Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
265
resultados
Última actualización
27/04/2026 [08:33:00]
Resultados 125 a 150 de 265
Resumen de: US20260078413A1
0000 The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Resumen de: WO2026059502A1
Various embodiments relate generally to the use of EPAS1 inhibitors for treating or preventing cerebral hypoperfusion, or a disease or condition associated with cerebral hypoperfusion, in a subject. Moreover, various embodiments also relate to methods for diagnosing, or predicting a subject's risk of developing, cerebral hypoperfusion, or a disease or condition associated with cerebral hypoperfusion, preferably a cerebrovascular disease, based upon identified biomarker.
Resumen de: WO2026057545A1
The present disclosure relates to novel antibodies and antigen-binding fragments thereof that specifically bind to human stimulator of interferon genes (STING), and uses of these antibodies and antigen-binding fragments thereof for treating diseases and disorders (e.g., inflammatory diseases or an autoimmune diseases).
Resumen de: US20260079168A1
0000 The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).
Resumen de: WO2026055750A1
The present disclosure relates to the field of oligonucleotides. More particularly, the present disclosure relates to antisense oligonucleotides for the specific binding and inhibition of translation of Chitinase (CHIT1) encoding mRNA. Additionally, this disclosure relates to methods of using such oligonucleotides in preventing or treating diseases, disorders or conditions associated with CHIT1, such as neurodegenerative or neuroinflammatory diseases, disorders or conditions like ALS.
Resumen de: WO2026060258A1
Disclosed herein is the use of gut microbiome (GM) as a therapeutic target for Parkinson's Disease (PD). Metagenomic biomarkers are identified that can stratify patients based on their dysbiotic features. Therefore, also disclosed is a companion diagnostic designed to identify patients that can be treated with an inhibitor of microbially induced amyloid.
Resumen de: WO2026060271A1
Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.
Resumen de: WO2026060193A1
Binding reagents for tau protein variants, including antibodies that bind to tau protein, and uses thereof are disclosed. The uses include determining if a patient has or is at risk of developing a tauopathy, and treating a patient having a tauopathy.
Resumen de: US20260079151A1
0000 A 3D immunomechanical model of myeloid cells for use in basic research and drug screening that allows for observation of the myeloid-mechanical interaction in the context of a range of different mechanical and immunological-related diseases. The model is also suitable for applications such as high-throughput drug screening and experiments in a microgravity environment such as low earth orbit.
Resumen de: KR102781029B1
The present invention provides a gene expression biomarker panel specific for diagnosis of amnestic mild cognitive impairment, which is a symptom of early Alzheimer's disease, as well as protein biomarkers for predicting MCI-to-AD conversion from mild cognitive impairment to Alzheimer's dementia. In addition, the diagnostic composition for analyzing gene expression and protein concentration changes in blood according to the present invention can provide a basis for selecting patients with early dementia who are expected to have a clinical effect in which the maximum therapeutic effect on anti-amyloid antibody drugs is predicted, that is, a decrease in cognitive function is delayed or stopped. In addition, the diagnostic composition according to the present invention can be used as an index for monitoring the therapeutic effect of minimum-invasion and evaluating prognosis by presenting data on changes in gene expression level and protein concentration from blood during the treatment process of Alzheimer's dementia.
Resumen de: AU2026201500A1
Abstract Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.
Resumen de: WO2026059929A1
Methods and systems disclosed herein can improve the quality of blood-derived samples (e.g., whole blood, serum, or plasma sample). In an aspect, the present disclosure provides a method of evaluating a plasma sample quality, comprising collecting a blood sample from a subject; processing the blood sample to separate a plasma sample from other blood components; quantitatively measuring amounts of one or more analytes present in the plasma sample, wherein the one or more analytes comprise hemoglobin, potassium (K), lactate, or formaldehyde (CH2O); and evaluating the quality of the plasma sample based at least in part on the measured amounts, wherein the measured amounts are indicative of the plasma sample quality. In another aspect, the present disclosure provides a method of adjusting for preanalytical bias utilizing a linear regression model to improve a signal to noise ratio, thereby potentially enhancing the performance of a classification model.
Resumen de: US20260079158A1
Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.
Resumen de: AU2024319662A1
The disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase treatment (e.g., asfotase alfa), an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphatasia (HPP). The methods include diagnosing a subject as having the presence of neutralizing antibodies that affect the efficacy of treatment, administering a treatment suitable for reducing the deleterious effects of neutralizing antibodies, and continuing alkaline phosphatase treatment.
Resumen de: US20260079170A1
0000 The present disclosure provides methods and materials for screening a compound or monitoring a subject's response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: EP4710932A1
The invention relates to composition comprising manganese, a solvate or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease in a subject, wherein the subject's cells have fewer than half the number of functional endoplasmic reticulum and mitochondria contact sites than the cells from a subject not suffering from the disease, and to an in vitro method for designing a personalised therapy to a subject suffering from a disease, comprising determining the mtDNA synthesis rate in a biological sample isolate from the subject in the presence and absence of Mn.
Resumen de: EP4711764A2
0001 Systems and methods for obtaining qualitative or quantitative measurements of proteoforms of polypeptides are described. The described methods include measurements of affinity reagent binding on single-molecule polypeptide arrays to distinguish between polypeptide isoforms. The described methods may provide high resolution quantitative comparisons of proteoforms with very low copy numbers.
Resumen de: CN121399472A
The present invention relates to a nasal fluid sample obtained from a subject, the nasal fluid sample comprising one or more marker protein amyloid beta (A beta), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for use in a method for aiding in the diagnosis of a degenerative disease of the nervous system, and to the use of a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for aiding in the diagnosis of a degenerative disease of the nervous system. The invention further relates to a method for aiding the diagnosis of a nervous system degenerative disease in a subject/individual.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: MX2022001817A
The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R- tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Nº publicación: CN121679036A 17/03/2026
Solicitante:
江苏默乐生物科技股份有限公司
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
BOPI
Sede Electrónica
